Would you like to receive more information about STRIBILD?
Cobicistat is an inhibitor of, and is metabolized by, CYP3A and CYP2D6. Elvitegravir is metabolized by CYP3A. STRIBILD is contraindicated with the following drugs due to the potential for serious and/or life-threatening events or loss of efficacy and development of possible resistance to STRIBILD.1
|Drug class||Drug name|
|Alpha 1-adrenoreceptor antagonist||alfuzosin|
|Ergot derivatives||dihydroergotamine, ergotamine, methylergonovine|
|GI motility agent||cisapride|
|Herbal products||St. John’s wort|
|HMG-CoA reductase inhibitors||lovastatin, simvastatin|
|PDE-5 inhibitor||sildenafil when dosed as Revatio® for the treatment of pulmonary arterial hypertension|
|Sedative/hypnotics||triazolam, orally administered midazolam|
STRIBILD is a complete regimen for the treatment of HIV-1 infection and should not be administered with other antiretroviral products.1
Emtricitabine and tenofovir, components of STRIBILD, are primarily excreted by the kidneys by a combination of glomerular filtration and active tubular secretion; therefore, coadministration of STRIBILD with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of emtricitabine and tenofovir, and the risk of adverse reactions.1
|CYP3A substrates||CYP3A inducers||Acid-reducing agents|
Consult the full Prescribing Information for STRIBILD for more information on potentially significant drug interactions, including clinical comments.
STRIBILD is indicated as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral (ARV) treatment history or to replace the current ARV regimen in adults who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable ARV regimen for ≥6 months with no history of treatment failure and no known resistance to any component of STRIBILD.
By following this link, you are now leaving www.STRIBILD.com/hcp. This site is not controlled by Gilead Sciences, Inc. Gilead Sciences, Inc. is not responsible for the site’s content or your use of the site.